<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880631</url>
  </required_header>
  <id_info>
    <org_study_id>360051-001</org_study_id>
    <nct_id>NCT02880631</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ In Resistant Hypertension</brief_title>
  <official_title>BAROSTIM THERAPY™ In Resistant Hypertension: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM
      NEO System in the commercial setting in subjects recently implanted under the CE-Marked
      indication for resistant hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Blood Pressure Changes from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Medication Changes from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>Medication name, dose, frequency, and start/stop date will be assessed over the 6 month time interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations over Follow-Up</measure>
    <time_frame>12 months post-implant</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barostim Neo™ System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects can be included in the Hypertension Registry if they were implanted in the past 30
        days and meet the CE-Mark approved indications and contraindications for the BAROSTIM NEO
        System in the treatment of resistant hypertension.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has signed an EC approved informed consent form

          -  Has been implanted with the BAROSTIM NEO system in the past 30 days

          -  Systolic blood pressure greater than or equal to 140 mmHg, and

          -  Resistance to maximally tolerated therapy with a diuretic and two other
             anti-hypertension medications

        Exclusion Criteria:

          -  Bilateral carotid bifurcations located above the level of the mandible

          -  Baroreflex failure or autonomic neuropathy

          -  Uncontrolled, symptomatic cardiac bradyarrhythmias

          -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to
             be greater than 50%

          -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannes Reuter, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Herzzentrum Uniklinik Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CVRx Vice President of Clinical Research</last_name>
    <phone>763-416-2876</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Immanual Kilikum Bernau</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Bettin</last_name>
      <phone>+49-3338-694604</phone>
      <email>d.bettin@immanuel.de</email>
    </contact>
    <investigator>
      <last_name>Christian Butter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital Cloppenburg gemainnutzige gGmbH</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Venneklaas</last_name>
      <phone>+49 4471-16 2955</phone>
      <email>ulla.venneklaas@kk-om.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Luders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center 'CVC' Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60398</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine De Bruijn</last_name>
      <phone>+49 69 97347653</phone>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Leibig University Giessen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Hellwig</last_name>
      <phone>0641-985-42632</phone>
      <email>gabriele.hellwig@med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Jorn Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburg - Asklepios Kliniken</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Neumann</last_name>
      <phone>+49 401818818635</phone>
      <email>chris.neumann@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Jochen Muller-Ehmsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schleswig-Hostein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anika Struve</last_name>
      <phone>+49-431-500-22915</phone>
      <email>anika.struve@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Hendrik Bonnemeier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Schewior</last_name>
      <phone>+49-221-478-88273</phone>
      <email>Tatjana.schewior@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Hannes Reuter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Dietrich</last_name>
      <phone>+49 (341) 97 12 408</phone>
      <email>jenny.dietrich@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Janine Starke</last_name>
      <phone>+49 (341) 97 12 443f</phone>
      <email>janine.starke@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Neef</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kilnikum Lippe GmbH</name>
      <address>
        <city>Lippe</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Kriete</last_name>
      <phone>05231 172-5727</phone>
      <email>melanie.kriete@klinikum-lippe.de</email>
    </contact>
    <investigator>
      <last_name>Kirk Haertel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marien-Krankenhaus Seigen gem. GmbH</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Blanke</last_name>
      <phone>02711-231-1215</phone>
      <email>c.blanke@marienkrankenhaus.com</email>
    </contact>
    <investigator>
      <last_name>Michael Buerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital and MVS Maria-Hilf Stadtlohn GmbH</name>
      <address>
        <city>Stadtlohn</city>
        <zip>489703</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Fitz</last_name>
      <phone>02563-912-6370</phone>
      <email>b.fitz@kmh-stadtlohn.de</email>
    </contact>
    <investigator>
      <last_name>Alessandro Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landkreis Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Weber</last_name>
      <phone>07461 97 1415</phone>
      <email>i.weber@klinikum-tut.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kotzerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun Klinikum</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Plottner</last_name>
      <phone>0375512138</phone>
      <email>heike.ploettner@hbk-zwickau.de</email>
    </contact>
    <investigator>
      <last_name>Jens Gerth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Center Maastricht, B.V.</name>
      <address>
        <city>Maastricht</city>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Jongen</last_name>
      <phone>+31-43-3877366</phone>
      <email>h.jongen@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Bram Kroon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010 Oct 5;56(15):1254-8. doi: 10.1016/j.jacc.2010.03.089.</citation>
    <PMID>20883933</PMID>
  </reference>
  <reference>
    <citation>Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 9;58(7):765-73. doi: 10.1016/j.jacc.2011.06.008.</citation>
    <PMID>21816315</PMID>
  </reference>
  <reference>
    <citation>Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr;6(2):152-8. doi: 10.1016/j.jash.2012.01.003. Epub 2012 Feb 15.</citation>
    <PMID>22341199</PMID>
  </reference>
  <reference>
    <citation>Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012 Jul-Aug;6(4):270-6. doi: 10.1016/j.jash.2012.04.004. Epub 2012 Jun 12.</citation>
    <PMID>22694986</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

